GSK (NYSE: GSK) director adds ADS through 401(k) dividend reinvestment

Rhea-AI Filing Summary

GSK plc reported that non-executive director Dr Hal Barron acquired additional American Depositary Shares through his GSK 401(k) plan. The purchase resulted from the reinvestment of dividends, leading to the acquisition of 64 ADS at a price of $59.5200 per ADS.

The transaction took place on 2026-02-20 on the New York Stock Exchange (XNYS). This reflects automatic plan-based dividend reinvestment rather than an open‑market discretionary trade.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.5200	64
			d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-02-20
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 25, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc



FAQ

What insider transaction did GSK (GSK) disclose in this report?

GSK disclosed that non-executive director Dr Hal Barron acquired 64 American Depositary Shares through his GSK 401(k) plan. The shares were purchased via automatic dividend reinvestment rather than a discretionary open-market trade, as detailed in the February 2026 report.

How many GSK (GSK) ADS did Dr Hal Barron acquire and at what price?

Dr Hal Barron acquired 64 GSK American Depositary Shares at a price of $59.5200 per ADS. The acquisition occurred automatically within his GSK 401(k) plan account following the reinvestment of dividends credited to that retirement plan.

When and where did Dr Hal Barron’s GSK (GSK) ADS transaction occur?

The transaction occurred on 2026-02-20 on the New York Stock Exchange (XNYS). GSK’s filing specifies that the American Depositary Shares were acquired through dividend reinvestment within Dr Barron’s GSK 401(k) plan, rather than through a separate brokered purchase.

What is the nature of Dr Hal Barron’s role at GSK (GSK)?

Dr Hal Barron is identified as a non-executive director of GSK plc. As a non-executive director, he serves on the board and is considered a person discharging managerial responsibilities for regulatory reporting of transactions in GSK securities.

What type of financial instrument did GSK (GSK) report in this transaction?

The transaction involved GSK American Depositary Shares, identified by ISIN US37733W2044. These ADS represent an interest in GSK’s ordinary shares and are listed and traded on the New York Stock Exchange, where the reported acquisition took place.

How was the price information for the GSK (GSK) ADS transaction presented?

The filing lists a single price of $59.5200 for the 64 ADS acquired, indicating a single aggregated transaction. Aggregated information is marked as not applicable beyond this, because the purchase resulted from one dividend reinvestment event in the 401(k) plan.